



# Supplementary Figure 1



**Supplementary Figure 1. Amubarvimab and romlusevimab exhibited extended *in vivo* serum half-life in cynomolgus monkeys.** (A B) Mean serum concentration profiles of amubarvimab (A) and romlusevimab (B) in 3 male and female cynomolgus monkeys over 8-weeks following a single intravenous administration of 10 mg/kg.

# Supplementary Figure 2



**Supplementary Figure 1. The neutralizing activity of amubarvimab and romlusevimab is comparable to their respective unmodified precursor antibodies P2C-1F11 and P2B-1G5.** *In vitro* neutralization of wild-type pseudovirus (A, C) or authentic live virus (B, D) with amubarvimab and romlusevimab and their precursor mAbs P2C-1F11 and P2B-1G5. Results are representative of at least two independent experiments.